Holmium-166 DOTMP

Drug Profile

Holmium-166 DOTMP

Alternative Names: Ho-DOTMP; Skeletal targeted radiotherapy; STR

Latest Information Update: 10 May 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dow Chemical
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma

Highest Development Phases

  • Discontinued Cancer metastases; Multiple myeloma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 10 May 2005 Discontinued - Phase-I for Cancer metastases in USA (Injection)
  • 10 May 2005 Discontinued - Phase-III for Multiple myeloma in Canada (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top